1. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1: Considering consequences of the immune response to a protein;Rosenberg;BioPharm Int.,2004
2. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2: Considering host-specific and product-specific factors impacting immunogenicity;Rosenberg;BioPharm Int.,2004
3. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 3: Effects of manufacturing changes on immunogenicity studies;Rosenberg;BioPharm Int.,2005
4. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk;Thorland;Haemophilia,1999
5. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report;Hartung;J. Neurol.,2007